Abstract:Fibroblast growth factor (FGF) signaling encompasses a multitude of functions, including regulation of cell proliferation, differentiation, morphogenesis, and patterning. FGFs and their receptors (FGFR) are crucial for adult tissue repair processes. Aberrant FGF signal transduction is associated with various pathological conditions such as cartilage damage, bone loss, muscle reduction, and other core pathological changes observed in orthopedic degenerative diseases like osteoarthritis (OA), intervertebral disc degeneration (IVDD), osteoporosis (OP), and sarcopenia. In OA and IVDD pathologies specifically, FGF1, FGF2, FGF8, FGF9, FGF18, FGF21, and FGF23 regulate the synthesis, catabolism, and ossification of cartilage tissue. Additionally, the dysregulation of FGFR expression (FGFR1 and FGFR3) promotes the pathological process of cartilage degradation. In OP and sarcopenia, endocrine-derived FGFs (FGF19, FGF21, and FGF23) modulate bone mineral synthesis and decomposition as well as muscle tissues. FGF2 and other FGFs also exert regulatory roles. A growing body of research has focused on understanding the implications of FGF signaling in orthopedic degeneration. Moreover, an increasing number of potential targets within the FGF signaling have been identified, such as FGF9, FGF18, and FGF23. However, it should be noted that most of these discoveries are still in the experimental stage, and further studies are needed before clinical application can be considered. Presently, this review aims to document the association between the FGF signaling pathway and the development and progression of orthopedic diseases. Besides, current therapeutic strategies targeting the FGF signaling pathway to prevent and treat orthopedic degeneration will be evaluated.

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve This paper aims to explore the role of the Fibroblast Growth Factor (FGF) signaling pathway in orthopedic degenerative diseases and its potential therapeutic targets. Specifically, the paper focuses on the following points: 1. **Relationship between FGF signaling pathway and orthopedic diseases**: - The paper provides a detailed introduction to the mechanisms of action of FGF family members and their receptors (FGFR) in various orthopedic degenerative diseases (such as osteoarthritis, intervertebral disc degeneration, osteoporosis, and sarcopenia). - It particularly points out that abnormalities in the FGF signaling pathway can lead to pathological changes such as cartilage damage, bone loss, and muscle reduction. 2. **Roles of different FGF members**: - The paper describes in detail the roles of FGF1, FGF2, FGF8, FGF9, FGF18, and FGF23 in osteoarthritis. - It highlights how these FGF members affect cartilage synthesis, degradation, and bone tissue signaling, leading to cartilage destruction and other symptoms. 3. **Impact of downstream signaling pathways**: - The paper analyzes several major downstream signaling pathways of the FGF signaling pathway (such as RAS-MAPK, PI3K-Akt, PLC-γ, and STAT) and how these pathways regulate cell proliferation, differentiation, and apoptosis. - It emphasizes the interactions between the FGF signaling pathway and these downstream pathways and proposes directions for further research. 4. **Evaluation of therapeutic strategies**: - The paper also evaluates current therapeutic methods targeting the FGF signaling pathway, particularly the application of FGF18 in clinical trials. - It proposes potential future therapeutic targets, including members like FGF9 and FGF18. In summary, this paper aims to comprehensively elucidate the mechanisms of the FGF signaling pathway in orthopedic degenerative diseases and evaluate its potential as a therapeutic target.

Role of signaling pathways in age-related orthopedic diseases: focus on the fibroblast growth factor family